Table 2.
Cox Proportional Hazard Model for PFS in Patients Treated with Irinotecan-Based and Oxaliplatin-Based Regimens.
| Variable | Irinotecan-Based Regimens (N = 35) | Oxaliplatin-Based Regimens (N = 83) | ||||||||||
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||||
| HR* | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age | 1.00 | .74 | .86 | .48 | ||||||||
| ≤50 | 1.00 | 1.00 | 1.00 | 0.51–1.75 | 1.00 | |||||||
| >50 | 1.00 | 0.37–2.74 | 1.22 | 0.38–3.97 | 0.95 | 0.78 | 0.39–1.55 | |||||
| Sex | .36 | .45 | .13 | .01 | ||||||||
| Female | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Male | 0.69 | 0.31–1.53 | 0.66 | 0.22–1.96 | 0.68 | 0.42–1.12 | 0.46 | 0.26–0.82 | ||||
| KRAS | .22 | .32 | .008 | .003 | ||||||||
| Mutant | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Wild type | 0.61 | 0.28–1.34 | 0.61 | 0.23–1.60 | 2.09 | 1.21–3.62 | 2.46 | 1.37–4.43 | ||||
| Initial diagnosis as stage IV | .30 | .44 | .23 | .13 | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Yes | 0.65 | 0.29–1.46 | 0.67 | 0.25–1.83 | 1.44 | 0.79–2.62 | 1.68 | 0.85–3.31 | ||||
| Tumor site | .72 | .92 | .94 | .33 | ||||||||
| Distal | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Proximal | 1.19 | 0.46–3.07 | 0.95 | 0.33–2.72 | 0.98 | 0.58–1.65 | 0.71 | 0.36–1.41 | ||||
| No. of metastatic sites | ||||||||||||
| 1 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| 2 | 0.83 | 0.35–1.93 | .66 | 0.87 | 0.25–3.05 | .83 | 1.28 | 0.76–2.17 | .36 | 1.45 | 0.81–2.59 | .21 |
| ≥3 | 1.88 | 0.40–8.91 | .43 | 1.97 | 0.39–10.00 | .41 | 4.28 | 1.61–11.37 | .004 | 3.87 | 1.28–11.68 | .02 |
*
HR, hazard ratio.